SCHEMBL4674891

SCHEMBL4674891

COc1ccc(Cc2cscc2C(=O)C=C(O)C(=O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
SAE1 Q9UBE0 1/20 0.39
UBA2 Q9UBT2 1/20 0.39
LTA4H P09960 1/20 0.39
FTO Q9C0B1 1/20 0.39
LDHA P00338 1/20 0.38
CTBP2 P56545 1/20 0.38
TAAR1 Q96RJ0 1/20 0.37
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 1/20 0.36
ALOX12 P18054 1/20 0.36
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674889 1.00 ALDH1A1 (0.40) ALDH1A1SAE1UBA2LTA4HFTO
SCHEMBL4680962 0.86 SRD5A2 (0.37) ALDH1A1CTBP2LMNAMAPTSMN1; SMN2
SCHEMBL4680966 0.86 SRD5A2 (0.37) ALDH1A1CTBP2LMNAMAPTSMN1; SMN2
SCHEMBL4677260 0.84 CYP2C9 (0.41) FTOCYP2C9
SCHEMBL4677257 0.84 CYP2C9 (0.41) FTOCYP2C9
SCHEMBL4676089 0.84 KMT2A (0.45) ALDH1A1LMNANPC1SMN1; SMN2CYP2C9
SCHEMBL4676086 0.84 KMT2A (0.45) ALDH1A1LMNANPC1SMN1; SMN2CYP2C9
SCHEMBL4671187 0.83 CYP2C9 (0.36) ALDH1A1CTBP2LMNASMN1; SMN2CYP2C9
SCHEMBL4673157 0.83 CYP2C9 (0.36) ALDH1A1CYP3A4CYP2C9
SCHEMBL4673159 0.83 CYP2C9 (0.36) ALDH1A1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885SAE1 2206/4885UBA2 1072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.